+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Acute Intravenous Injection of Two Growth Hormone-Releasing Hormones (GHRH 1–40 and 1–29) on Serum Growth Hormone and Other Pituitary Hormones in Short Children with Pulsatile Growth Hormone Secretion

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We administered two different growth hormone-releasing hormones (GHRH) to 20 short, prepubertal children who had spontaneous secretion of growth hormone (GH), assessed from 24-hour GH secretion profiles (72 sampling periods of 20 min). We compared one i.v. injection of 1 µg/kg of GHRH 1–40 with that of GHRH 1–29 regarding serum concentrations of GH, prolactin, luteinizing hormone, follicle-stimulating hormone and IGF-I. The children were allocated to two groups without statistical randomization. Both groups were given both peptides, with at least 1 week in between. The first group started with GHRH 1–40, the other with GHRH 1–29. The peptides both induced an increased serum concentration of GH of the same magnitude: mean maximal peak of 89 ± 12 mU/1 after GHRH 1–40 and 94 ± 10 mU/1 after GHRH 1–29 (n.s.). The mean difference in maximum serum GH concentration in each child after injection was 52 ± 9 mU/1, range 1–153 mU/1. GHRH 1–29 also induced a short-term, small increase in the concentrations of prolactin (p < 0.05), luteinizing hormone (p < 0.01) and follicle-stimulating hormone (p < 0.05). We conclude that the shorter sequence GHRH 1–29, when given in a dose of 1 µg/kg, gives a rise in serum concentration of GH similar to that after the native form GHRH 1–40.

          Related collections

          Author and article information

          Hormone Research in Paediatrics
          S. Karger AG
          02 December 2008
          : 31
          : 5-6
          : 213-220
          Departments of aPaediatrics II, bClinical Chemistry, and cPhysiology, Gothenburg University, Sweden; dEndocrine Division, Department of Physiology, University of Umeå, Sweden; eDepartment of Clinical Chemistry, University of Uppsala, Sweden
          181119 Horm Res 1989;31:213–220
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article